APO Research
Talk to an analyst

APO RESEARCH · REPORT

NASH Drug Pipeline

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global NASH Drug Pipeline Market Analysis and Forecast 2026-2032

2 January 2026218 pages

Choose your research edition.

Industry ResearchNASH Drug Pipeline Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal NASH Drug Pipeline Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal NASH Drug Pipeline Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NASH Drug Pipeline Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal NASH Drug Pipeline Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global NASH Drug Pipeline market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for NASH Drug Pipeline is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for NASH Drug Pipeline is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for NASH Drug Pipeline is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for NASH Drug Pipeline is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of NASH Drug Pipeline include 89bio Inc, ABIONYX Pharma SA, Abivax SA, Abliva AB, Acquist Therapeutics, AdAlta Ltd, Afimmune Biopharma Ltd, Allergan and ChemomAb Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for NASH Drug Pipeline, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of NASH Drug Pipeline, also provides the sales of main regions and countries. Of the upcoming market potential for NASH Drug Pipeline, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the NASH Drug Pipeline sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global NASH Drug Pipeline market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for NASH Drug Pipeline sales, projected growth trends, production technology, application and end-user industry.

NASH Drug Pipeline Segment by Company

89bio Inc

ABIONYX Pharma SA

Abivax SA

Abliva AB

Acquist Therapeutics

AdAlta Ltd

Afimmune Biopharma Ltd

Allergan

ChemomAb Ltd

Dicerna Pharmaceuticals Inc

DURECT Corp

Eli Lilly and Co

Enanta Pharmaceuticals Inc

EncuraGen Inc

Engitix Ltd

Galectin

Genfit

Gilead

Heprotech Inc

Hinova Pharmaceuticals Inc

HK inno.N Corp

HotSpot Therapeutics Inc

Immuron

Intercept

Madrigal

Zhejiang Doer Biologics Corp

NASH Drug Pipeline Segment by Type

By Molecule Types

By Route of Administration:

By Mechanism of Action

NASH Drug Pipeline Segment by Application

Clinical

Academic Research

NASH Drug Pipeline Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NASH Drug Pipeline market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NASH Drug Pipeline and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NASH Drug Pipeline.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of NASH Drug Pipeline in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of NASH Drug Pipeline manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NASH Drug Pipeline sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global NASH Drug Pipeline Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Type I Major Manufacturers Table 3. Type II Major Manufacturers Table 4. Global NASH Drug Pipeline Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Clinical Major Manufacturers Table 6. Academic Research Major Manufacturers Table 7. NASH Drug Pipeline Industry Trends Table 8. NASH Drug Pipeline Industry Drivers Table 9. NASH Drug Pipeline Industry Opportunities and Challenges Table 10. NASH Drug Pipeline Industry Restraints Table 11. Global NASH Drug Pipeline Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global NASH Drug Pipeline Revenue by Region (2021-2026) & (US$ Million) Table 13. Global NASH Drug Pipeline Revenue by Region (2027-2032) & (US$ Million) Table 14. Global NASH Drug Pipeline Revenue Market Share by Region (2021-2026) Table 15. Global NASH Drug Pipeline Revenue Market Share by Region (2027-2032) Table 16. Global NASH Drug Pipeline Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 17. Global NASH Drug Pipeline Sales by Region (2021-2026) & (K Units) Table 18. Global NASH Drug Pipeline Sales by Region (2027-2032) & (K Units) Table 19. Global NASH Drug Pipeline Sales Market Share by Region (2021-2026) Table 20. Global NASH Drug Pipeline Sales Market Share by Region (2027-2032) Table 21. Global NASH Drug Pipeline Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global NASH Drug Pipeline Revenue Market Share by Manufacturers (2021-2026) Table 23. Global NASH Drug Pipeline Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global NASH Drug Pipeline Sales Market Share by Manufacturers (2021-2026) Table 25. Global NASH Drug Pipeline Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global NASH Drug Pipeline Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global NASH Drug Pipeline Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global NASH Drug Pipeline Manufacturers, Product Type & Application Table 29. Global NASH Drug Pipeline Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global NASH Drug Pipeline by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global NASH Drug Pipeline Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global NASH Drug Pipeline Revenue by Type (2021-2026) & (US$ Million) Table 34. Global NASH Drug Pipeline Revenue by Type (2027-2032) & (US$ Million) Table 35. Global NASH Drug Pipeline Revenue Market Share by Type (2021-2026) Table 36. Global NASH Drug Pipeline Revenue Market Share by Type (2027-2032) Table 37. Global NASH Drug Pipeline Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 38. Global NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 39. Global NASH Drug Pipeline Sales by Type (2027-2032) & (K Units) Table 40. Global NASH Drug Pipeline Sales Market Share by Type (2021-2026) Table 41. Global NASH Drug Pipeline Sales Market Share by Type (2027-2032) Table 42. Global NASH Drug Pipeline Price by Type (2021-2026) & (US$/Unit) Table 43. Global NASH Drug Pipeline Price by Type (2027-2032) & (US$/Unit) Table 44. Global NASH Drug Pipeline Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global NASH Drug Pipeline Revenue by Application (2021-2026) & (US$ Million) Table 46. Global NASH Drug Pipeline Revenue by Application (2027-2032) & (US$ Million) Table 47. Global NASH Drug Pipeline Revenue Market Share by Application (2021-2026) Table 48. Global NASH Drug Pipeline Revenue Market Share by Application (2027-2032) Table 49. Global NASH Drug Pipeline Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 50. Global NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 51. Global NASH Drug Pipeline Sales by Application (2027-2032) & (K Units) Table 52. Global NASH Drug Pipeline Sales Market Share by Application (2021-2026) Table 53. Global NASH Drug Pipeline Sales Market Share by Application (2027-2032) Table 54. Global NASH Drug Pipeline Price by Application (2021-2026) & (US$/Unit) Table 55. Global NASH Drug Pipeline Price by Application (2027-2032) & (US$/Unit) Table 56. 89bio Inc Company Information Table 57. 89bio Inc Business Overview Table 58. 89bio Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. 89bio Inc NASH Drug Pipeline Product Portfolio Table 60. 89bio Inc Recent Development Table 61. ABIONYX Pharma SA Company Information Table 62. ABIONYX Pharma SA Business Overview Table 63. ABIONYX Pharma SA NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. ABIONYX Pharma SA NASH Drug Pipeline Product Portfolio Table 65. ABIONYX Pharma SA Recent Development Table 66. Abivax SA Company Information Table 67. Abivax SA Business Overview Table 68. Abivax SA NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Abivax SA NASH Drug Pipeline Product Portfolio Table 70. Abivax SA Recent Development Table 71. Abliva AB Company Information Table 72. Abliva AB Business Overview Table 73. Abliva AB NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Abliva AB NASH Drug Pipeline Product Portfolio Table 75. Abliva AB Recent Development Table 76. Acquist Therapeutics Company Information Table 77. Acquist Therapeutics Business Overview Table 78. Acquist Therapeutics NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Acquist Therapeutics NASH Drug Pipeline Product Portfolio Table 80. Acquist Therapeutics Recent Development Table 81. AdAlta Ltd Company Information Table 82. AdAlta Ltd Business Overview Table 83. AdAlta Ltd NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. AdAlta Ltd NASH Drug Pipeline Product Portfolio Table 85. AdAlta Ltd Recent Development Table 86. Afimmune Biopharma Ltd Company Information Table 87. Afimmune Biopharma Ltd Business Overview Table 88. Afimmune Biopharma Ltd NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolio Table 90. Afimmune Biopharma Ltd Recent Development Table 91. Allergan Company Information Table 92. Allergan Business Overview Table 93. Allergan NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Allergan NASH Drug Pipeline Product Portfolio Table 95. Allergan Recent Development Table 96. ChemomAb Ltd Company Information Table 97. ChemomAb Ltd Business Overview Table 98. ChemomAb Ltd NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. ChemomAb Ltd NASH Drug Pipeline Product Portfolio Table 100. ChemomAb Ltd Recent Development Table 101. Dicerna Pharmaceuticals Inc Company Information Table 102. Dicerna Pharmaceuticals Inc Business Overview Table 103. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio Table 105. Dicerna Pharmaceuticals Inc Recent Development Table 106. DURECT Corp Company Information Table 107. DURECT Corp Business Overview Table 108. DURECT Corp NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. DURECT Corp NASH Drug Pipeline Product Portfolio Table 110. DURECT Corp Recent Development Table 111. Eli Lilly and Co Company Information Table 112. Eli Lilly and Co Business Overview Table 113. Eli Lilly and Co NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Eli Lilly and Co NASH Drug Pipeline Product Portfolio Table 115. Eli Lilly and Co Recent Development Table 116. Enanta Pharmaceuticals Inc Company Information Table 117. Enanta Pharmaceuticals Inc Business Overview Table 118. Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio Table 120. Enanta Pharmaceuticals Inc Recent Development Table 121. EncuraGen Inc Company Information Table 122. EncuraGen Inc Business Overview Table 123. EncuraGen Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. EncuraGen Inc NASH Drug Pipeline Product Portfolio Table 125. EncuraGen Inc Recent Development Table 126. Engitix Ltd Company Information Table 127. Engitix Ltd Business Overview Table 128. Engitix Ltd NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Engitix Ltd NASH Drug Pipeline Product Portfolio Table 130. Engitix Ltd Recent Development Table 131. Galectin Company Information Table 132. Galectin Business Overview Table 133. Galectin NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Galectin NASH Drug Pipeline Product Portfolio Table 135. Galectin Recent Development Table 136. Genfit Company Information Table 137. Genfit Business Overview Table 138. Genfit NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Genfit NASH Drug Pipeline Product Portfolio Table 140. Genfit Recent Development Table 141. Gilead Company Information Table 142. Gilead Business Overview Table 143. Gilead NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Gilead NASH Drug Pipeline Product Portfolio Table 145. Gilead Recent Development Table 146. Heprotech Inc Company Information Table 147. Heprotech Inc Business Overview Table 148. Heprotech Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Heprotech Inc NASH Drug Pipeline Product Portfolio Table 150. Heprotech Inc Recent Development Table 151. Hinova Pharmaceuticals Inc Company Information Table 152. Hinova Pharmaceuticals Inc Business Overview Table 153. Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio Table 155. Hinova Pharmaceuticals Inc Recent Development Table 156. HK inno.N Corp Company Information Table 157. HK inno.N Corp Business Overview Table 158. HK inno.N Corp NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. HK inno.N Corp NASH Drug Pipeline Product Portfolio Table 160. HK inno.N Corp Recent Development Table 161. HotSpot Therapeutics Inc Company Information Table 162. HotSpot Therapeutics Inc Business Overview Table 163. HotSpot Therapeutics Inc NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolio Table 165. HotSpot Therapeutics Inc Recent Development Table 166. Immuron Company Information Table 167. Immuron Business Overview Table 168. Immuron NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Immuron NASH Drug Pipeline Product Portfolio Table 170. Immuron Recent Development Table 171. Intercept Company Information Table 172. Intercept Business Overview Table 173. Intercept NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. Intercept NASH Drug Pipeline Product Portfolio Table 175. Intercept Recent Development Table 176. Madrigal Company Information Table 177. Madrigal Business Overview Table 178. Madrigal NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 179. Madrigal NASH Drug Pipeline Product Portfolio Table 180. Madrigal Recent Development Table 181. Zhejiang Doer Biologics Corp Company Information Table 182. Zhejiang Doer Biologics Corp Business Overview Table 183. Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 184. Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolio Table 185. Zhejiang Doer Biologics Corp Recent Development Table 186. North America NASH Drug Pipeline Revenue by Type (2021-2026) & (US$ Million) Table 187. North America NASH Drug Pipeline Revenue by Type (2027-2032) & (US$ Million) Table 188. North America NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 189. North America NASH Drug Pipeline Sales by Type (2027-2032) & (K Units) Table 190. North America NASH Drug Pipeline Sales Price by Type (2021-2026) & (US$/Unit) Table 191. North America NASH Drug Pipeline Sales Price by Type (2027-2032) & (US$/Unit) Table 192. North America NASH Drug Pipeline Revenue by Application (2021-2026) & (US$ Million) Table 193. North America NASH Drug Pipeline Revenue by Application (2027-2032) & (US$ Million) Table 194. North America NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 195. North America NASH Drug Pipeline Sales by Application (2027-2032) & (K Units) Table 196. North America NASH Drug Pipeline Sales Price by Application (2021-2026) & (US$/Unit) Table 197. North America NASH Drug Pipeline Sales Price by Application (2027-2032) & (US$/Unit) Table 198. North America NASH Drug Pipeline Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 199. North America NASH Drug Pipeline Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 200. North America NASH Drug Pipeline Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 201. North America NASH Drug Pipeline Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 202. North America NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 203. North America NASH Drug Pipeline Sales by Country (2027-2032) & (K Units) Table 204. North America NASH Drug Pipeline Sales Price by Country (2021-2026) & (US$/Unit) Table 205. North America NASH Drug Pipeline Sales Price by Country (2027-2032) & (US$/Unit) Table 206. United States NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 207. Canada NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 208. Europe NASH Drug Pipeline Revenue by Type (2021-2026) & (US$ Million) Table 209. Europe NASH Drug Pipeline Revenue by Type (2027-2032) & (US$ Million) Table 210. Europe NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 211. Europe NASH Drug Pipeline Sales by Type (2027-2032) & (K Units) Table 212. Europe NASH Drug Pipeline Sales Price by Type (2021-2026) & (US$/Unit) Table 213. Europe NASH Drug Pipeline Sales Price by Type (2027-2032) & (US$/Unit) Table 214. Europe NASH Drug Pipeline Revenue by Application (2021-2026) & (US$ Million) Table 215. Europe NASH Drug Pipeline Revenue by Application (2027-2032) & (US$ Million) Table 216. Europe NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 217. Europe NASH Drug Pipeline Sales by Application (2027-2032) & (K Units) Table 218. Europe NASH Drug Pipeline Sales Price by Application (2021-2026) & (US$/Unit) Table 219. Europe NASH Drug Pipeline Sales Price by Application (2027-2032) & (US$/Unit) Table 220. Europe NASH Drug Pipeline Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 221. Europe NASH Drug Pipeline Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 222. Europe NASH Drug Pipeline Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 223. Europe NASH Drug Pipeline Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 224. Europe NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 225. Europe NASH Drug Pipeline Sales by Country (2027-2032) & (K Units) Table 226. Europe NASH Drug Pipeline Sales Price by Country (2021-2026) & (US$/Unit) Table 227. Europe NASH Drug Pipeline Sales Price by Country (2027-2032) & (US$/Unit) Table 228. Germany NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 229. France NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 230. U.K. NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 231. Italy NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 232. Netherlands NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 233. China NASH Drug Pipeline Revenue by Type (2021-2026) & (US$ Million) Table 234. China NASH Drug Pipeline Revenue by Type (2027-2032) & (US$ Million) Table 235. China NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 236. China NASH Drug Pipeline Sales by Type (2027-2032) & (K Units) Table 237. China NASH Drug Pipeline Sales Price by Type (2021-2026) & (US$/Unit) Table 238. China NASH Drug Pipeline Sales Price by Type (2027-2032) & (US$/Unit) Table 239. China NASH Drug Pipeline Revenue by Application (2021-2026) & (US$ Million) Table 240. China NASH Drug Pipeline Revenue by Application (2027-2032) & (US$ Million) Table 241. China NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 242. China NASH Drug Pipeline Sales by Application (2027-2032) & (K Units) Table 243. China NASH Drug Pipeline Sales Price by Application (2021-2026) & (US$/Unit) Table 244. China NASH Drug Pipeline Sales Price by Application (2027-2032) & (US$/Unit) Table 245. Asia NASH Drug Pipeline Revenue by Type (2021-2026) & (US$ Million) Table 246. Asia NASH Drug Pipeline Revenue by Type (2027-2032) & (US$ Million) Table 247. Asia NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 248. Asia NASH Drug Pipeline Sales by Type (2027-2032) & (K Units) Table 249. Asia NASH Drug Pipeline Sales Price by Type (2021-2026) & (US$/Unit) Table 250. Asia NASH Drug Pipeline Sales Price by Type (2027-2032) & (US$/Unit) Table 251. Asia NASH Drug Pipeline Revenue by Application (2021-2026) & (US$ Million) Table 252. Asia NASH Drug Pipeline Revenue by Application (2027-2032) & (US$ Million) Table 253. Asia NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 254. Asia NASH Drug Pipeline Sales by Application (2027-2032) & (K Units) Table 255. Asia NASH Drug Pipeline Sales Price by Application (2021-2026) & (US$/Unit) Table 256. Asia NASH Drug Pipeline Sales Price by Application (2027-2032) & (US$/Unit) Table 257. Asia NASH Drug Pipeline Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 258. Asia NASH Drug Pipeline Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 259. Asia NASH Drug Pipeline Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 260. Asia NASH Drug Pipeline Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 261. Asia NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 262. Asia NASH Drug Pipeline Sales by Country (2027-2032) & (K Units) Table 263. Asia NASH Drug Pipeline Sales Price by Country (2021-2026) & (US$/Unit) Table 264. Asia NASH Drug Pipeline Sales Price by Country (2027-2032) & (US$/Unit) Table 265. Japan NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 266. South Korea NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 267. India NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 268. Australia NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 269. China Taiwan NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 270. Southeast Asia NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 271. SAMEA NASH Drug Pipeline Revenue by Type (2021-2026) & (US$ Million) Table 272. SAMEA NASH Drug Pipeline Revenue by Type (2027-2032) & (US$ Million) Table 273. SAMEA NASH Drug Pipeline Sales by Type (2021-2026) & (K Units) Table 274. SAMEA NASH Drug Pipeline Sales by Type (2027-2032) & (K Units) Table 275. SAMEA NASH Drug Pipeline Sales Price by Type (2021-2026) & (US$/Unit) Table 276. SAMEA NASH Drug Pipeline Sales Price by Type (2027-2032) & (US$/Unit) Table 277. SAMEA NASH Drug Pipeline Revenue by Application (2021-2026) & (US$ Million) Table 278. SAMEA NASH Drug Pipeline Revenue by Application (2027-2032) & (US$ Million) Table 279. SAMEA NASH Drug Pipeline Sales by Application (2021-2026) & (K Units) Table 280. SAMEA NASH Drug Pipeline Sales by Application (2027-2032) & (K Units) Table 281. SAMEA NASH Drug Pipeline Sales Price by Application (2021-2026) & (US$/Unit) Table 282. SAMEA NASH Drug Pipeline Sales Price by Application (2027-2032) & (US$/Unit) Table 283. SAMEA NASH Drug Pipeline Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 284. SAMEA NASH Drug Pipeline Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 285. SAMEA NASH Drug Pipeline Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 286. SAMEA NASH Drug Pipeline Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 287. SAMEA NASH Drug Pipeline Sales by Country (2021-2026) & (K Units) Table 288. SAMEA NASH Drug Pipeline Sales by Country (2027-2032) & (K Units) Table 289. SAMEA NASH Drug Pipeline Sales Price by Country (2021-2026) & (US$/Unit) Table 290. SAMEA NASH Drug Pipeline Sales Price by Country (2027-2032) & (US$/Unit) Table 291. Brazil NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 292. Argentina NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 293. Chile NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 294. Colombia NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 295. Peru NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 296. Saudi Arabia NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 297. Israel NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 298. UAE NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 299. Turkey NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 300. Iran NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 301. Egypt NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Table 302. Key Raw Materials Table 303. Raw Materials Key Suppliers Table 304. NASH Drug Pipeline Distributors List Table 305. NASH Drug Pipeline Customers List Table 306. Research Programs/Design for This Report Table 307. Authors List of This Report Table 308. Secondary Sources Table 309. Primary Sources List of Figures Figure 1. NASH Drug Pipeline Image Figure 2. Global NASH Drug Pipeline Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NASH Drug Pipeline Market Size Share 2021 VS 2025 VS 2032 Figure 4. Type I Image Figure 5. Type II Image Figure 6. Global NASH Drug Pipeline Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global NASH Drug Pipeline Market Size Share 2021 VS 2025 VS 2032 Figure 8. Clinical Image Figure 9. Academic Research Image Figure 10. Global NASH Drug Pipeline Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global NASH Drug Pipeline Revenue (2021-2032) & (US$ Million) Figure 12. Global NASH Drug Pipeline Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global NASH Drug Pipeline Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global NASH Drug Pipeline Revenue Market Share by Region (2021-2032) Figure 15. Global NASH Drug Pipeline Sales (2021-2032) & (K Units) Figure 16. Global NASH Drug Pipeline Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 17. Global NASH Drug Pipeline Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico NASH Drug Pipeline Sales YoY (2021-2032) & (K Units) Figure 19. Europe NASH Drug Pipeline Sales YoY (2021-2032) & (K Units) Figure 20. China NASH Drug Pipeline Sales YoY (2021-2032) & (K Units) Figure 21. Asia (Excluding China) NASH Drug Pipeline Sales YoY (2021-2032) & (K Units) Figure 22. South America, Middle East and Africa NASH Drug Pipeline Sales YoY (2021-2032) & (K Units) Figure 23. Global NASH Drug Pipeline Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global NASH Drug Pipeline Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global NASH Drug Pipeline Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global NASH Drug Pipeline Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global NASH Drug Pipeline Revenue Market Share by Type (2021-2032) Figure 29. Global NASH Drug Pipeline Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global NASH Drug Pipeline Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global NASH Drug Pipeline Sales Market Share by Type (2021-2032) Figure 32. Global NASH Drug Pipeline Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global NASH Drug Pipeline Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global NASH Drug Pipeline Revenue Market Share by Application (2021-2032) Figure 35. Global NASH Drug Pipeline Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global NASH Drug Pipeline Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global NASH Drug Pipeline Sales Market Share by Application (2021-2032) Figure 38. North America NASH Drug Pipeline Revenue Share by Type (2021-2032) Figure 39. North America NASH Drug Pipeline Sales Share by Type (2021-2032) Figure 40. North America NASH Drug Pipeline Revenue Share by Application (2021-2032) Figure 41. North America NASH Drug Pipeline Sales Share by Application (2021-2032) Figure 42. North America NASH Drug Pipeline Revenue Share by Country (2021-2032) Figure 43. North America NASH Drug Pipeline Sales Share by Country (2021-2032) Figure 44. Europe NASH Drug Pipeline Revenue Share by Type (2021-2032) Figure 45. Europe NASH Drug Pipeline Sales Share by Type (2021-2032) Figure 46. Europe NASH Drug Pipeline Revenue Share by Application (2021-2032) Figure 47. Europe NASH Drug Pipeline Sales Share by Application (2021-2032) Figure 48. Europe NASH Drug Pipeline Revenue Share by Country (2021-2032) Figure 49. Europe NASH Drug Pipeline Sales Share by Country (2021-2032) Figure 50. China NASH Drug Pipeline Revenue Share by Type (2021-2032) Figure 51. China NASH Drug Pipeline Sales Share by Type (2021-2032) Figure 52. China NASH Drug Pipeline Revenue Share by Application (2021-2032) Figure 53. China NASH Drug Pipeline Sales Share by Application (2021-2032) Figure 54. Asia NASH Drug Pipeline Revenue Share by Type (2021-2032) Figure 55. Asia NASH Drug Pipeline Sales Share by Type (2021-2032) Figure 56. Asia NASH Drug Pipeline Revenue Share by Application (2021-2032) Figure 57. Asia NASH Drug Pipeline Sales Share by Application (2021-2032) Figure 58. Asia NASH Drug Pipeline Revenue Share by Country (2021-2032) Figure 59. Asia NASH Drug Pipeline Sales Share by Country (2021-2032) Figure 60. SAMEA NASH Drug Pipeline Revenue Share by Type (2021-2032) Figure 61. SAMEA NASH Drug Pipeline Sales Share by Type (2021-2032) Figure 62. SAMEA NASH Drug Pipeline Revenue Share by Application (2021-2032) Figure 63. SAMEA NASH Drug Pipeline Sales Share by Application (2021-2032) Figure 64. SAMEA NASH Drug Pipeline Revenue Share by Country (2021-2032) Figure 65. SAMEA NASH Drug Pipeline Sales Share by Country (2021-2032) Figure 66. NASH Drug Pipeline Value Chain Figure 67. Manufacturing Cost Structure Figure 68. NASH Drug Pipeline Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Applications
  • Clinical
  • Academic Research
Companies covered
  • 89bio Inc
  • ABIONYX Pharma SA
  • Abivax SA
  • Abliva AB
  • Acquist Therapeutics
  • AdAlta Ltd
  • Afimmune Biopharma Ltd
  • Allergan
  • ChemomAb Ltd
  • Dicerna Pharmaceuticals Inc
  • DURECT Corp
  • Eli Lilly and Co
  • Enanta Pharmaceuticals Inc
  • EncuraGen Inc
  • Engitix Ltd
  • Galectin
  • Genfit
  • Gilead
  • Heprotech Inc
  • Hinova Pharmaceuticals Inc
  • HK inno.N Corp
  • HotSpot Therapeutics Inc
  • Immuron
  • Intercept
  • Madrigal
  • Zhejiang Doer Biologics Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 NASH Drug Pipeline Market by Type
  3. 1.2.1 Global NASH Drug Pipeline Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 By Molecule Types
  5. 1.2.3 By Route of Administration:
  6. 1.2.4 By Mechanism of Action
  7. 1.3 NASH Drug Pipeline Market by Application
  8. 1.3.1 Global NASH Drug Pipeline Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Clinical
  10. 1.3.3 Academic Research
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 NASH Drug Pipeline Market Dynamics
  1. 2.1 NASH Drug Pipeline Industry Trends
  2. 2.2 NASH Drug Pipeline Industry Drivers
  3. 2.3 NASH Drug Pipeline Industry Opportunities and Challenges
  4. 2.4 NASH Drug Pipeline Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global NASH Drug Pipeline Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global NASH Drug Pipeline Revenue by Region
  3. 3.2.1 Global NASH Drug Pipeline Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global NASH Drug Pipeline Revenue by Region (2021-2026)
  5. 3.2.3 Global NASH Drug Pipeline Revenue by Region (2027-2032)
  6. 3.2.4 Global NASH Drug Pipeline Revenue Market Share by Region (2021-2032)
  7. 3.3 Global NASH Drug Pipeline Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global NASH Drug Pipeline Sales by Region
  9. 3.4.1 Global NASH Drug Pipeline Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global NASH Drug Pipeline Sales by Region (2021-2026)
  11. 3.4.3 Global NASH Drug Pipeline Sales by Region (2027-2032)
  12. 3.4.4 Global NASH Drug Pipeline Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global NASH Drug Pipeline Revenue by Manufacturers
  2. 4.1.1 Global NASH Drug Pipeline Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global NASH Drug Pipeline Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global NASH Drug Pipeline Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global NASH Drug Pipeline Sales by Manufacturers
  6. 4.2.1 Global NASH Drug Pipeline Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global NASH Drug Pipeline Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global NASH Drug Pipeline Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global NASH Drug Pipeline Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global NASH Drug Pipeline Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global NASH Drug Pipeline Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global NASH Drug Pipeline Manufacturers, Product Type & Application
  13. 4.7 Global NASH Drug Pipeline Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global NASH Drug Pipeline Market CR5 and HHI
  16. 4.8.2 2025 NASH Drug Pipeline Tier 1, Tier 2, and Tier 3
5 NASH Drug Pipeline Market by Type
  1. 5.1 Global NASH Drug Pipeline Revenue by Type
  2. 5.1.1 Global NASH Drug Pipeline Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global NASH Drug Pipeline Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global NASH Drug Pipeline Revenue Market Share by Type (2021-2032)
  5. 5.2 Global NASH Drug Pipeline Sales by Type
  6. 5.2.1 Global NASH Drug Pipeline Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global NASH Drug Pipeline Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global NASH Drug Pipeline Sales Market Share by Type (2021-2032)
  9. 5.3 Global NASH Drug Pipeline Price by Type
6 NASH Drug Pipeline Market by Application
  1. 6.1 Global NASH Drug Pipeline Revenue by Application
  2. 6.1.1 Global NASH Drug Pipeline Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global NASH Drug Pipeline Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global NASH Drug Pipeline Revenue Market Share by Application (2021-2032)
  5. 6.2 Global NASH Drug Pipeline Sales by Application
  6. 6.2.1 Global NASH Drug Pipeline Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global NASH Drug Pipeline Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global NASH Drug Pipeline Sales Market Share by Application (2021-2032)
  9. 6.3 Global NASH Drug Pipeline Price by Application
7 Company Profiles
  1. 7.1 89bio Inc
  2. 7.1.1 89bio Inc Company Information
  3. 7.1.2 89bio Inc Business Overview
  4. 7.1.3 89bio Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 89bio Inc NASH Drug Pipeline Product Portfolio
  6. 7.1.5 89bio Inc Recent Developments
  7. 7.2 ABIONYX Pharma SA
  8. 7.2.1 ABIONYX Pharma SA Company Information
  9. 7.2.2 ABIONYX Pharma SA Business Overview
  10. 7.2.3 ABIONYX Pharma SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 ABIONYX Pharma SA NASH Drug Pipeline Product Portfolio
  12. 7.2.5 ABIONYX Pharma SA Recent Developments
  13. 7.3 Abivax SA
  14. 7.3.1 Abivax SA Company Information
  15. 7.3.2 Abivax SA Business Overview
  16. 7.3.3 Abivax SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Abivax SA NASH Drug Pipeline Product Portfolio
  18. 7.3.5 Abivax SA Recent Developments
  19. 7.4 Abliva AB
  20. 7.4.1 Abliva AB Company Information
  21. 7.4.2 Abliva AB Business Overview
  22. 7.4.3 Abliva AB NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Abliva AB NASH Drug Pipeline Product Portfolio
  24. 7.4.5 Abliva AB Recent Developments
  25. 7.5 Acquist Therapeutics
  26. 7.5.1 Acquist Therapeutics Company Information
  27. 7.5.2 Acquist Therapeutics Business Overview
  28. 7.5.3 Acquist Therapeutics NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Acquist Therapeutics NASH Drug Pipeline Product Portfolio
  30. 7.5.5 Acquist Therapeutics Recent Developments
  31. 7.6 AdAlta Ltd
  32. 7.6.1 AdAlta Ltd Company Information
  33. 7.6.2 AdAlta Ltd Business Overview
  34. 7.6.3 AdAlta Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 AdAlta Ltd NASH Drug Pipeline Product Portfolio
  36. 7.6.5 AdAlta Ltd Recent Developments
  37. 7.7 Afimmune Biopharma Ltd
  38. 7.7.1 Afimmune Biopharma Ltd Company Information
  39. 7.7.2 Afimmune Biopharma Ltd Business Overview
  40. 7.7.3 Afimmune Biopharma Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolio
  42. 7.7.5 Afimmune Biopharma Ltd Recent Developments
  43. 7.8 Allergan
  44. 7.8.1 Allergan Company Information
  45. 7.8.2 Allergan Business Overview
  46. 7.8.3 Allergan NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Allergan NASH Drug Pipeline Product Portfolio
  48. 7.8.5 Allergan Recent Developments
  49. 7.9 ChemomAb Ltd
  50. 7.9.1 ChemomAb Ltd Company Information
  51. 7.9.2 ChemomAb Ltd Business Overview
  52. 7.9.3 ChemomAb Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 ChemomAb Ltd NASH Drug Pipeline Product Portfolio
  54. 7.9.5 ChemomAb Ltd Recent Developments
  55. 7.10 Dicerna Pharmaceuticals Inc
  56. 7.10.1 Dicerna Pharmaceuticals Inc Company Information
  57. 7.10.2 Dicerna Pharmaceuticals Inc Business Overview
  58. 7.10.3 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
  60. 7.10.5 Dicerna Pharmaceuticals Inc Recent Developments
  61. 7.11 DURECT Corp
  62. 7.11.1 DURECT Corp Company Information
  63. 7.11.2 DURECT Corp Business Overview
  64. 7.11.3 DURECT Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 DURECT Corp NASH Drug Pipeline Product Portfolio
  66. 7.11.5 DURECT Corp Recent Developments
  67. 7.12 Eli Lilly and Co
  68. 7.12.1 Eli Lilly and Co Company Information
  69. 7.12.2 Eli Lilly and Co Business Overview
  70. 7.12.3 Eli Lilly and Co NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Eli Lilly and Co NASH Drug Pipeline Product Portfolio
  72. 7.12.5 Eli Lilly and Co Recent Developments
  73. 7.13 Enanta Pharmaceuticals Inc
  74. 7.13.1 Enanta Pharmaceuticals Inc Company Information
  75. 7.13.2 Enanta Pharmaceuticals Inc Business Overview
  76. 7.13.3 Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
  78. 7.13.5 Enanta Pharmaceuticals Inc Recent Developments
  79. 7.14 EncuraGen Inc
  80. 7.14.1 EncuraGen Inc Company Information
  81. 7.14.2 EncuraGen Inc Business Overview
  82. 7.14.3 EncuraGen Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 EncuraGen Inc NASH Drug Pipeline Product Portfolio
  84. 7.14.5 EncuraGen Inc Recent Developments
  85. 7.15 Engitix Ltd
  86. 7.15.1 Engitix Ltd Company Information
  87. 7.15.2 Engitix Ltd Business Overview
  88. 7.15.3 Engitix Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Engitix Ltd NASH Drug Pipeline Product Portfolio
  90. 7.15.5 Engitix Ltd Recent Developments
  91. 7.16 Galectin
  92. 7.16.1 Galectin Company Information
  93. 7.16.2 Galectin Business Overview
  94. 7.16.3 Galectin NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Galectin NASH Drug Pipeline Product Portfolio
  96. 7.16.5 Galectin Recent Developments
  97. 7.17 Genfit
  98. 7.17.1 Genfit Company Information
  99. 7.17.2 Genfit Business Overview
  100. 7.17.3 Genfit NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Genfit NASH Drug Pipeline Product Portfolio
  102. 7.17.5 Genfit Recent Developments
  103. 7.18 Gilead
  104. 7.18.1 Gilead Company Information
  105. 7.18.2 Gilead Business Overview
  106. 7.18.3 Gilead NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Gilead NASH Drug Pipeline Product Portfolio
  108. 7.18.5 Gilead Recent Developments
  109. 7.19 Heprotech Inc
  110. 7.19.1 Heprotech Inc Company Information
  111. 7.19.2 Heprotech Inc Business Overview
  112. 7.19.3 Heprotech Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Heprotech Inc NASH Drug Pipeline Product Portfolio
  114. 7.19.5 Heprotech Inc Recent Developments
  115. 7.20 Hinova Pharmaceuticals Inc
  116. 7.20.1 Hinova Pharmaceuticals Inc Company Information
  117. 7.20.2 Hinova Pharmaceuticals Inc Business Overview
  118. 7.20.3 Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  119. 7.20.4 Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolio
  120. 7.20.5 Hinova Pharmaceuticals Inc Recent Developments
  121. 7.21 HK inno.N Corp
  122. 7.21.1 HK inno.N Corp Company Information
  123. 7.21.2 HK inno.N Corp Business Overview
  124. 7.21.3 HK inno.N Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  125. 7.21.4 HK inno.N Corp NASH Drug Pipeline Product Portfolio
  126. 7.21.5 HK inno.N Corp Recent Developments
  127. 7.22 HotSpot Therapeutics Inc
  128. 7.22.1 HotSpot Therapeutics Inc Company Information
  129. 7.22.2 HotSpot Therapeutics Inc Business Overview
  130. 7.22.3 HotSpot Therapeutics Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  131. 7.22.4 HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolio
  132. 7.22.5 HotSpot Therapeutics Inc Recent Developments
  133. 7.23 Immuron
  134. 7.23.1 Immuron Company Information
  135. 7.23.2 Immuron Business Overview
  136. 7.23.3 Immuron NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  137. 7.23.4 Immuron NASH Drug Pipeline Product Portfolio
  138. 7.23.5 Immuron Recent Developments
  139. 7.24 Intercept
  140. 7.24.1 Intercept Company Information
  141. 7.24.2 Intercept Business Overview
  142. 7.24.3 Intercept NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  143. 7.24.4 Intercept NASH Drug Pipeline Product Portfolio
  144. 7.24.5 Intercept Recent Developments
  145. 7.25 Madrigal
  146. 7.25.1 Madrigal Company Information
  147. 7.25.2 Madrigal Business Overview
  148. 7.25.3 Madrigal NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  149. 7.25.4 Madrigal NASH Drug Pipeline Product Portfolio
  150. 7.25.5 Madrigal Recent Developments
  151. 7.26 Zhejiang Doer Biologics Corp
  152. 7.26.1 Zhejiang Doer Biologics Corp Company Information
  153. 7.26.2 Zhejiang Doer Biologics Corp Business Overview
  154. 7.26.3 Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2021-2026)
  155. 7.26.4 Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolio
  156. 7.26.5 Zhejiang Doer Biologics Corp Recent Developments
8 North America
  1. 8.1 North America NASH Drug Pipeline Market Size by Type
  2. 8.1.1 North America NASH Drug Pipeline Revenue by Type (2021-2032)
  3. 8.1.2 North America NASH Drug Pipeline Sales by Type (2021-2032)
  4. 8.1.3 North America NASH Drug Pipeline Price by Type (2021-2032)
  5. 8.2 North America NASH Drug Pipeline Market Size by Application
  6. 8.2.1 North America NASH Drug Pipeline Revenue by Application (2021-2032)
  7. 8.2.2 North America NASH Drug Pipeline Sales by Application (2021-2032)
  8. 8.2.3 North America NASH Drug Pipeline Price by Application (2021-2032)
  9. 8.3 North America NASH Drug Pipeline Market Size by Country
  10. 8.3.1 North America NASH Drug Pipeline Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America NASH Drug Pipeline Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America NASH Drug Pipeline Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe NASH Drug Pipeline Market Size by Type
  2. 9.1.1 Europe NASH Drug Pipeline Revenue by Type (2021-2032)
  3. 9.1.2 Europe NASH Drug Pipeline Sales by Type (2021-2032)
  4. 9.1.3 Europe NASH Drug Pipeline Price by Type (2021-2032)
  5. 9.2 Europe NASH Drug Pipeline Market Size by Application
  6. 9.2.1 Europe NASH Drug Pipeline Revenue by Application (2021-2032)
  7. 9.2.2 Europe NASH Drug Pipeline Sales by Application (2021-2032)
  8. 9.2.3 Europe NASH Drug Pipeline Price by Application (2021-2032)
  9. 9.3 Europe NASH Drug Pipeline Market Size by Country
  10. 9.3.1 Europe NASH Drug Pipeline Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe NASH Drug Pipeline Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe NASH Drug Pipeline Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China NASH Drug Pipeline Market Size by Type
  2. 10.1.1 China NASH Drug Pipeline Revenue by Type (2021-2032)
  3. 10.1.2 China NASH Drug Pipeline Sales by Type (2021-2032)
  4. 10.1.3 China NASH Drug Pipeline Price by Type (2021-2032)
  5. 10.2 China NASH Drug Pipeline Market Size by Application
  6. 10.2.1 China NASH Drug Pipeline Revenue by Application (2021-2032)
  7. 10.2.2 China NASH Drug Pipeline Sales by Application (2021-2032)
  8. 10.2.3 China NASH Drug Pipeline Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia NASH Drug Pipeline Market Size by Type
  2. 11.1.1 Asia NASH Drug Pipeline Revenue by Type (2021-2032)
  3. 11.1.2 Asia NASH Drug Pipeline Sales by Type (2021-2032)
  4. 11.1.3 Asia NASH Drug Pipeline Price by Type (2021-2032)
  5. 11.2 Asia NASH Drug Pipeline Market Size by Application
  6. 11.2.1 Asia NASH Drug Pipeline Revenue by Application (2021-2032)
  7. 11.2.2 Asia NASH Drug Pipeline Sales by Application (2021-2032)
  8. 11.2.3 Asia NASH Drug Pipeline Price by Application (2021-2032)
  9. 11.3 Asia NASH Drug Pipeline Market Size by Country
  10. 11.3.1 Asia NASH Drug Pipeline Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia NASH Drug Pipeline Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia NASH Drug Pipeline Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA NASH Drug Pipeline Market Size by Type
  2. 12.1.1 SAMEA NASH Drug Pipeline Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA NASH Drug Pipeline Sales by Type (2021-2032)
  4. 12.1.3 SAMEA NASH Drug Pipeline Price by Type (2021-2032)
  5. 12.2 SAMEA NASH Drug Pipeline Market Size by Application
  6. 12.2.1 SAMEA NASH Drug Pipeline Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA NASH Drug Pipeline Sales by Application (2021-2032)
  8. 12.2.3 SAMEA NASH Drug Pipeline Price by Application (2021-2032)
  9. 12.3 SAMEA NASH Drug Pipeline Market Size by Country
  10. 12.3.1 SAMEA NASH Drug Pipeline Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA NASH Drug Pipeline Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA NASH Drug Pipeline Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 NASH Drug Pipeline Value Chain Analysis
  2. 13.1.1 NASH Drug Pipeline Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 NASH Drug Pipeline Production Mode & Process
  6. 13.2 NASH Drug Pipeline Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 NASH Drug Pipeline Distributors
  9. 13.2.3 NASH Drug Pipeline Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst